Provided by Tiger Trade Technology Pte. Ltd.

Soleno Therapeutics

41.53
+1.954.93%
Post-market: 41.05-0.4800-1.16%19:57 EST
Volume:1.46M
Turnover:59.51M
Market Cap:2.23B
PE:-23.73
High:41.80
Open:40.32
Low:39.55
Close:39.58
52wk High:90.32
52wk Low:37.95
Shares:53.71M
Float Shares:44.87M
Volume Ratio:0.65
T/O Rate:3.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7500
EPS(LYR):-4.3770
ROE:-20.66%
ROA:-11.75%
PB:4.51
PE(LYR):-9.49

Loading ...

Company Profile

Company Name:
Soleno Therapeutics
Exchange:
NASDAQ
Establishment Date:
1999
Employees:
152
Office Location:
100 Marine Parkway,Suite 400,Redwood City,California,United States
Zip Code:
94065
Fax:
650 213 8383
Introduction:
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Directors

Name
Position
Anish Bhatnagar
CEO and Chairman of the Board
Matthew Pauls
Lead Independent Director
Andrew Sinclair
Director
Birgitte Volck
Director
Dawn Bir
Director
Mark W. Hahn
Director
William G. Harris
Director

Shareholders

Name
Position
James Mackaness
Chief Financial Officer
Kristen Yen
Senior Vice President of Global Clinical Operations and Patient Advocacy
Michael Huang
Senior Vice President of Clinical Development
Patricia Hirano
Senior Vice President of Regulatory Affairs
Anish Bhatnagar
CEO and Chairman of the Board
Meredith Manning
Chief Commercial Officer